Publications by authors named "Melissa S Bourque"
Article Synopsis
- Continuous infusion vancomycin (CIV) is beneficial for children in hematology/oncology who struggle to reach therapeutic drug levels with standard intermittent dosing, and it simplifies outpatient care by reducing dosing frequency.
- A study of 60 pediatric patients showed that the median total daily dose to achieve therapeutic levels (15-25 µg/mL) was about 50.3 mg/kg/day, with younger patients needing higher doses compared to older ones.
- The average time to reach therapeutic levels was around 19.3 hours, and serious side effects, like acute kidney injury, were rare, indicating CIV is a safe and effective treatment option.
Objective: We aimed to describe the effect of education provided by a clinical pharmacy specialist at a patient's follow-up appointment after discharge, and to assess caregiver satisfaction.
Methods: A single-center, quality improvement study was conducted. A standardized data collection tool was created to characterize interventions made by clinical pharmacy specialists during an outpatient clinic appointment scheduled shortly after discharge.
Objective: The purpose of this study was to compare acute kidney injury (AKI)-related outcomes of patients who received aminophylline in addition to standard of care with matched historical controls who received standard of care alone.
Methods: This was a single center, retrospective, historical control cohort study that included patients treated for AKI. Patients who received aminophylline from January 2017 to June 2018 were matched for age, sex, primary diagnosis, and hematopoietic cell transplant history in a 1:2 ratio to historical controls treated for AKI from July 2015 to September 2016.
Background: Posaconazole exhibits broad-spectrum antifungal activity. An IV formulation became available in 2014. Few studies describing the use of this formulation exist in patients under the age of 18 years.
View Article and Find Full Text PDF